The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection
Open accessAbstract
SIGNIFICANCE: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of cardiotoxicity. The most feared are the chronic forms of cardiotoxicity, characterized by irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be complex, the pivotal role has been traditionally attributed to the iron-mediated formation of reactive oxygen species (ROS). In clinics, the bisdioxopiperazine agent dexrazoxane (ICRF-187) reduces the risk of anthracycline cardiotoxicity without a significant effect on response to chemotherapy. The prevailing concept describes dexrazoxane as a prodrug undergoing bioactivation to an iron-chelating agent ADR-925, which may inhibit anthracycline-induced ROS formation and oxidative damage to cardiomyocytes. RECENT ADVANCES: A considerable body of evidence points to mitochondria as the key targets for anthracycline cardiotoxicity, and therefore it could be also crucial for effective cardioprotection. Numerous antioxidants and several iron chelators have been tested in vitro and in vivo with variable outcomes. None of these compounds have matched or even surpassed the effectiveness of dexrazoxane in chronic anthracycline cardiotoxicity settings, despite being stronger chelators and/or antioxidants. CRITICAL ISSUES: The interpretation of many findings is complicated by the heterogeneity of experimental models and frequent employment of acute high-dose treatments with limited translatability to clinical practice. FUTURE DIRECTIONS: Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Free Radicals in Biology and Medicine
Halliwell, B., & Gutteridge, J. M. C. (2015) · doi:10.1093/acprof:oso/9780198717478.001.0001 · Cited by 8,990
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Self-citationReduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 682
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Whitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 509
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., & St Clair, D. K. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118909 · Cited by 459
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Doxorubicin‐Induced Cardiac Mitochondrionopathy
Wallace, K. B. (2003) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2003.930301.x · Cited by 389
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 376
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Anthracycline Antibiotic Augmentation of Microsomal Electron Transport and Free Radical Formation
BACHUR, N. R., GORDON, S. L., & GEE, M. V. (1977) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12453-x · Cited by 373
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366
Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats
Walter, P. B., Knutson, M. D., Paler-Martinez, A., Lee, S., Xu, Y., Viteri, F. E., & Ames, B. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261708798 · Cited by 359
Stereochemistry of Intercalation: Interaction of Daunomycin with DNA
PIGRAM, W. J., FULLER, W., & HAMILTON, L. D. (1972) · Nature New Biology · doi:10.1038/newbio235017a0 · Cited by 358
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308033200 · Cited by 304
Kang, Y. J., Chen, Y., & Epstein, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12610 · Cited by 303
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe, K., Ikegami, Y., Ishida, R., & Andoh, T. (1991) · PubMed · Cited by 292
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995) · Circulation · doi:10.1161/01.cir.91.1.10 · Cited by 285
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, E., Ungvári, Z., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
Bonadonna, G., Monfardini, S., Lena, M. D., Fossati‐Bellani, F., & Beretta, G. (1970) · PubMed · Cited by 278
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.6.2829 · Cited by 265
Classen, S., Olland, S., & Berger, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832879100 · Cited by 263
Saad, S. Y., Najjar, T. A., & Al-Rikabi, A. C. (2001) · Pharmacological Research · doi:10.1006/phrs.2000.0769 · Cited by 259
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Rajagopalan, S., Politi, P. M., Sinha, B. K., & Myers, C. E. (1988) · PubMed · Cited by 248
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Zhao, Y., McLaughlin, D., Robinson, E., Harvey, A. P., Hookham, M. B., Shah, A. M., McDermott, B. J., & Grieve, D. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2664 · Cited by 244
Role of deferiprone in chelation therapy for transfusional iron overload
Hoffbrand, A. V., Cohen, A., & Hershko, C. (2003) · Blood · doi:10.1182/blood-2002-06-1867 · Cited by 244
Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex
Myers, C. E., Gianni, L., Simone, C. B., Klecker, R., & Greene, R. (1982) · Biochemistry · doi:10.1021/bi00537a001 · Cited by 239
Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39082-2 · Cited by 229
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Adams, M. J., & Lipshultz, S. E. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20352 · Cited by 224
Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats: In Vivo Study
Nakamura, T., Ueda, Y., Juan, Y., Katsuda, S., Takahashi, H., & Koh, E. (2000) · Circulation · doi:10.1161/01.cir.102.5.572 · Cited by 223
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J., & Walker, U. A. (2003) · Circulation · doi:10.1161/01.cir.0000093196.59829.df · Cited by 219
Daunorubicin-Induced Apoptosis in Rat Cardiac Myocytes Is Inhibited by Dexrazoxane
Sawyer, D. B., Fukazawa, R., Arstall, M. A., & Kelly, R. A. (1999) · Circulation Research · doi:10.1161/01.res.84.3.257 · Cited by 207
Kang, Y. J., Zhou, Z.-X., Wang, G.-W., Buridi, A., & Klein, J. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13690 · Cited by 207
Dexrazoxane: A Review of its Use for Cardioprotection During Anthracycline Chemotherapy
Cvetkovi??, R. S., & Scott, L. J. (2005) · Drugs · doi:10.2165/00003495-200565070-00008 · Cited by 203
Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B. L., & Stahalova, V. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj134 · Cited by 202
Glickstein, H., El, R. B., Link, G., Breuer, W., Konijn, A. M., Hershko, C., Nick, H., & Cabantchik, Z. I. (2006) · Blood · doi:10.1182/blood-2006-05-020867 · Cited by 201
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J.-M. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 200
Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., & Cairo, G. (2001) · PubMed · Cited by 200
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Geisberg, C. A., & Sawyer, D. B. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0146-y · Cited by 189
Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol
Li, T., & Singal, P. K. (2000) · Circulation · doi:10.1161/01.cir.102.17.2105 · Cited by 187
Tangpong, J., Cole, M. P., Sultana, R., Estus, S., Vore, M., St. Clair, W., Ratanachaiyavong, S., St. Clair, D. K., & Butterfield, D. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04179.x · Cited by 185
NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies
Sirker, A., Zhang, M., & Shah, A. M. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0190-z · Cited by 179
Menna, P., Gonzalez Paz, O., Chello, M., Covino, E., Salvatorelli, E., & Minotti, G. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.589834 · Cited by 177
Intralysosomal iron chelation protects against oxidative stress‐induced cellular damage
Kurz, T., Gustafsson, B., & Brunk, U. T. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05321.x · Cited by 175
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Molecular and cellular mechanisms of anthracycline cardiotoxicity
Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0005-5 · Cited by 172
Vleet, J. F. V., Ferrans, V. J., & Weirich, W. E. (1980) · PubMed · Cited by 169
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., & Santos, M. M. (2003) · Blood · doi:10.1182/blood-2003-03-0869 · Cited by 168
Goorin, A. M., Chauvenet, A. R., Perez-Atayde, A. R., Cruz, J., McKone, R., & Lipshultz, S. E. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81668-3 · Cited by 163
Cardiotoxicity of Antitumor Drugs
Menna, P., Salvatorelli, E., & Minotti, G. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800002r · Cited by 163
Serrano, J., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00011-0 · Cited by 159
Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
MAWDESLEY-THOMAS, L. E. (1972) · Nature · doi:10.1038/235017a0 · Cited by 158
Swain, S. M., & Vici, P. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0498-7 · Cited by 155
Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells
Gosálvez, M., Blanco, M., Hunter, J., et al. (1974) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(74)90044-9 · Cited by 153
van der Kraaij, A. M., van Eijk, H. G., & Koster, J. F. (1989) · Circulation · doi:10.1161/01.cir.80.1.158 · Cited by 152
Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex
Muindi, J. R., Sinha, B. K., Gianni, L., & Myers, C. E. (1984) · FEBS Letters · doi:10.1016/0014-5793(84)81130-8 · Cited by 150
A Pro-Chelator Triggered by Hydrogen Peroxide Inhibits Iron-Promoted Hydroxyl Radical Formation
Charkoudian, L. K., Pham, D. M., & Franz, K. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja064806w · Cited by 150
Marcillat, O., Zhang, Y., & Davies, K. J. A. (1989) · Biochemical Journal · doi:10.1042/bj2590181 · Cited by 149
Yen, H., Oberley, T. D., Gairola, C. G., Szweda, L. I., & Clair, D. K. S. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.1011 · Cited by 142
Doroshow, J. H. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90981-2 · Cited by 142
Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines
Hasinoff, B. B., Hellmann, K., Herman, E., & Ferrans, V. J. (1998) · Current Medicinal Chemistry · doi:10.2174/0929867305666220314194045 · Cited by 141
López, M., Vici, P., Lauro, K. D., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., & MAINI, C. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.86 · Cited by 140
Link, G., Tirosh, R., Pinson, A., & Hershko, C. (1996) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(96)90095-5 · Cited by 139
Lebrecht, D., Geist, A., Ketelsen, U., Haberstroh, J., Setzer, B., & Walker, U. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707294 · Cited by 136
Fogli, S., Nieri, P., & Breschi, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0724rev · Cited by 134
Lebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A. (2005) · The Journal of Pathology · doi:10.1002/path.1863 · Cited by 133
Davies, K. J. A., Doroshow, J. H., & Hochstein, P. E. (1983) · FEBS Letters · doi:10.1016/0014-5793(83)80153-7 · Cited by 132
Wiseman, L. R., & Spencer, C. M. (1998) · Drugs · doi:10.2165/00003495-199856030-00009 · Cited by 132
Jones, R. L., Swanton, C., & Ewer, M. S. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.6.791 · Cited by 132
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M., Bjork, J. A., & Wallace, K. B. (2010) · Toxicology · doi:10.1016/j.tox.2010.01.019 · Cited by 131
Kim, D., Kim, H., Woo, E., Hong, S., Chae, H., & Chae, S. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.06.026 · Cited by 129
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
Panjrath, G. S., Patel, V., Valdiviezo, C., Narula, N., Narula, J., & Jain, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.060 · Cited by 126
Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors
Hudson, M. M., Rai, S. N., Núnêz, C., Merchant, T. E., Marina, N. M., Zalamea, N. N., Cox, C. L., Phipps, S., Pompeu, R. G., & Rosenthal, D. N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7451 · Cited by 124
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
Gianni, L., Salvatorelli, E., & Minotti, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0013-5 · Cited by 122
Zhang, J. H. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0186 · Cited by 120
Herman, E., Ferrans, V. J., Myers, C. E., & Vleet, J. F. V. (1985) · PubMed · Cited by 120
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118
Herman, E. H., Zhang, J., Chadwick, D. P., & Ferrans, V. J. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050048 · Cited by 117
Release of iron from ferritin by cardiotoxic anthracycline antibiotics
Thomas, C. E., & Aust, S. D. (1986) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(86)90523-0 · Cited by 116
Disruption of Mitochondrial Calcium Homeostasis Following Chronic Doxorubicin Administration
Solem, L. E., Henry, T. R., & Wallace, K. B. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1246 · Cited by 116
Role of mtDNA lesions in anthracycline cardiotoxicity
Lebrecht, D., & Walker, U. A. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0009-1 · Cited by 115
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
Zuppinger, C., Timolati, F., & Suter, T. M. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0016-2 · Cited by 113
The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity
Cole, M. P., Chaiswing, L., Oberley, T. D., Edelmann, S. E., Piascik, M. T., LIN, S., Kiningham, K. K., & Clair, D. K. S. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.07.012 · Cited by 110
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats
Li, T. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00039-0 · Cited by 110
Anthracycline-Induced Cardiotoxicity
Hrdina, R., Geršl, V., Klimtová, I., Šimůnek, T., Macháčková, J., & Adamcová, M. (2000) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2019.117 · Cited by 110
Self-citationAnthracycline cardiotoxicity in long-term survivors of childhood cancer
Scully, R. E., & Lipshultz, S. E. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0006-4 · Cited by 109
Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A. D., Chai, J., & Ferrans, V. J. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100348 · Cited by 106
Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman, E., & Ferrans, V. J. (1998) · PubMed · Cited by 104
Adriamycin: amelioration of toxicity by alpha-tocopherol.
Myers, C. E., McGuire, W. P., & Young, R. C. (1976) · PubMed · Cited by 104
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats
Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., & Hayakawa, T. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00362-8 · Cited by 103
A Deletion of Mitochondrial DNA in Murine Doxorubicin-Induced Cardiotoxicity
Adachi, K., Fujiura, Y., Mayumi, F., Nozuhara, A., Sugiu, Y., Sakanashi, T., Hidaka, T., & Toshima, H. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2135 · Cited by 103
Berthiaume, J. M., Oliveira, P. J., Fariss, M. W., & Wallace, K. B. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:257 · Cited by 101
Berthiaume, J. M., & Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0026-0 · Cited by 99
Xiong, Y., Liu, X., Lee, C.-P., Chua, B. H. L., & Ho, Y.-S. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.02.024 · Cited by 96
Protective effect of flavonoids on doxorubicin-induced cardiotoxicity
Sadzuka, Y., Sugiyama, T., Shimoi, K., Kinae, N., & Hirota, S. (1997) · Toxicology Letters · doi:10.1016/s0378-4274(97)00028-3 · Cited by 95
Breed, J. G. S., Zimmerman, A. N. E., Dormans, J. A. M. A., & Pinedo, H. M. (1980) · PubMed · Cited by 94
Oliveira, P. J., & Wallace, K. B. (2006) · Toxicology · doi:10.1016/j.tox.2005.12.009 · Cited by 94
Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003) · Cardiovascular Toxicology · doi:10.1385/ct:3:2:89 · Cited by 91
Martin, E., Thougaard, A., Grauslund, M., Jensen, P. B., Björkling, F., Hasinoff, B. B., Tjørnelund, J., Sehested, M., & Jensen, L. H. (2008) · Toxicology · doi:10.1016/j.tox.2008.10.011 · Cited by 91
Yamaoka‐Tojo, M., Yamaguchi, S., Suzuki, T., Okuyama, M., Nitobe, J., Nakamura, N., Mitsui, Y., & Tomoike, H. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1132 · Cited by 90
Šimůnek, T., Boer, C., Bouwman, R. A., VLASBLOM, R., Versteilen, A. M. G., Štěrba, M., Geršl, V., Hrdina, R., Poňka, P., DELANGE, J., et al. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.05.008 · Cited by 90
Self-citationDeferiprone protects against doxorubicin-induced myocyte cytotoxicity
Barnabé, N., Zastre, J. A., Venkataram, S., & Hasinoff, B. B. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00873-0 · Cited by 87
Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
Molina‐Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J., & Hider, R. C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05332.x · Cited by 85
Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt, G., Dørup, I., Sørensen, K. E., & Sullivan, I. D. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04803.x · Cited by 84
Assessment of Anthracycline Cardiomyopathy by Endomyocardial Biopsy
Mackay, B., Ewer, M. S., Carrasco, C. H., & Benjamin, R. S. (1994) · Ultrastructural Pathology · doi:10.3109/01913129409016291 · Cited by 84
An introduction to the metabolic determinants of anthracycline cardiotoxicity
Menna, P., Recalcati, S., Cairo, G., & Minotti, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0011-7 · Cited by 83
Kwok, J., & Richardson, D. R. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.849 · Cited by 82
Potential Use of Iron Chelators against Oxidative Damage
Galey, J.-B. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60984-9 · Cited by 80
Genotyping the risk of anthracycline-induced cardiotoxicity
Deng, S., & Wojnowski, L. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0024-2 · Cited by 79
Seymour, L., Bramwell, V., & Moran, L. A. (1999) · PubMed · Cited by 78
Horackova, M. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00088-2 · Cited by 77
Tokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.516 · Cited by 75
Hershko, C., Link, G., Tzahor, M., Kaltwasser, J. P., Athias, P., Grynberg, A., & Pinson, A. (1993) · PubMed · Cited by 74
Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D. S., Kovarikova, P., Vavrova, K., et al. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100125t · Cited by 73 · cited 5×
“Even though Dp44mT has shown some tendency to increase ascorbate oxidation under cell-free conditions, it was the most potent agent in reduction of intracellular ROS production (15).”
InfluentialReduction of adriamycin toxicity by ascorbate in mice and guinea pigs.
Fujita, K., Shinpo, K., Yamada, K., Sato, T., Niimi, H., Shamoto, M., Nagatsu, T., TAKEUCHI, T., & UMEZAWA, H. (1982) · PubMed · Cited by 73
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Jansson, P. J., Hawkins, C. L., Lovejoy, D. B., & Richardson, D. R. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.07.012 · Cited by 72
Lukinova, N. I., Iacovelli, J., Dentchev, T., Wolkow, N., Hunter, A. A., Amado, D. A., Ying, G., Sparrow, J. R., & Dunaief, J. L. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2545 · Cited by 70
DNA topoisomerase-trapping antitumour drugs
Capranico, G., & Zunino, F. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90255-z · Cited by 69
Pathogenesis and prevention of doxorubicin cardiomyopathy.
Ferrans, V. J., Clark, J., Zhang, J., Yu, Z., & Herman, E. (1997) · PubMed · Cited by 68
Imondi, A. R., Torre, P. D., Mazué, G., Sullivan, T. M., Robbins, T. L., Hagerman, L. M., Podestà, A., & Pinciroli, G. (1996) · PubMed · Cited by 67
Hermes‐Lima, M., Nagy, E., Ponka, P., & Schulman, H. M. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00117-8 · Cited by 67
Proteomic insights into chronic anthracycline cardiotoxicity
Štěrba, M., Popelová, O., Lenčo, J., Fučíková, A., Doleželová, E., Mazurová, Y., Jirkovský, E., Šimůnek, T., Adamcová, M., Mičuda, S., et al. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.01.018 · Cited by 65
Self-citationChaiswing, L., Cole, M. P., Ittarat, W., Szweda, L. I., Clair, D. K. S., & Oberley, T. D. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0322 · Cited by 65
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834120aa · Cited by 63
Šimůnek, T., Klimtová, I., Kaplanová, J., Mazurová, Y., Adamcová, M., Štěrba, M., Hrdina, R., & Geršl, V. (2003) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.05.003 · Cited by 62
Self-citationJavadov, S. A., Hunter, J. C., Barreto‐Torres, G., & Parodi‐Rullán, R. M. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000327943 · Cited by 62
Popelová, O., Štěrba, M., Hašková, P., Šimůnek, T., Hroch, M., Gunčová, I., Nachtigal, P., Adamcová, M., Geršl, V., & Mazurová, Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605192 · Cited by 61
Self-citationHerman, E., Zhang, J., & Ferrans, V. J. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686629 · Cited by 56
Repta, A. J., Baltezor, M., & Bansal, P. C. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650216 · Cited by 56
Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity
Gao, J., Xiong, Y., Ho, Y.-S., Liu, X., Chua, C. C., Xu, X., Wang, H., Hamdy, R. C., & Chua, B. H. L. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.05.027 · Cited by 54
Kwok, J. C., & Richardson, D. R. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.4.888 · Cited by 54
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
Popelová, O., Štěrba, M., Šimůnek, T., Mazurová, Y., Němečková, I., Hroch, M., Adamcová, M., & Geršl, V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137604 · Cited by 53
Self-citationSpeyer, J. L., Green, M. D., Dubin, N., Blum, R. H., Wernz, J., Roses, D. F., Sanger, J. J., & Muggia, F. M. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90395-x · Cited by 52
Herman, E., Ferrans, V. J., Young, R. S. K., & Hamlin, R. L. (1988) · PubMed · Cited by 52
Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis
Lebrecht, D. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg564 · Cited by 51
Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction
Maslov, M. Y., Chacko, V. P., Hirsch, G. A., Akki, A. S., Leppo, M. K., Steenbergen, C., & Weiss, R. G. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00727.2009 · Cited by 50
Hasinoff, B. B., Schroeder, P. E., & Patel, D. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.670 · Cited by 50
Charkoudian, L. K., Dentchev, T., Lukinova, N., Wolkow, N., Dunaief, J. L., & Franz, K. J. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.08.001 · Cited by 49
Preliminary Clinical Experience with 4’-Epidoxorubicin in Advanced Human Neoplasia
Bonfante, V., Bonadonna, G., Villani, F., & Martini, A. (1980) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81488-4_24 · Cited by 49
Al-Harbi, M. M., Al-Gharably, N. M., Al‐Shabanah, O. A., Al‐Bekairi, A. M., Osman, A. M. M., & Tawfik, H. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685548 · Cited by 48
Šimůnek, T., Štěrba, M., Popelová, O., Mertlíková‐Kaiserová, H., Adamcová, M., Hroch, M., Hašková, P., Ponka, P., & Geršl, V. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.236 · Cited by 46
Self-citationInvestigation of the stability of aromatic hydrazones in plasma and related biological material
Kovaříková, P., Mrkvičková, Z., & Klimeš, J. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.01.011 · Cited by 44
Self-citationStudy of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits
Šimůnek, T., Klimtová, I., Kaplanová, J., Štěrba, M., Mazurová, Y., Adamcová, M., Hrdina, R., Geršl, V., & Poňka, P. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.08.005 · Cited by 44
Self-citationLong-term and short-term models for studying anthracycline cardiotoxicity and protectors
Robert, J. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0022-4 · Cited by 43
Štěrba, M., Popelová, O., Šimůnek, T., Mazurová, Y., Potáčová, A., Adamcová, M., Mertlíková‐Kaiserová, H., Poňka, P., & Geršl, V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111468 · Cited by 43
Self-citationComparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits
Klimtová, I., Šimůnek, T., Mazurová, Y., Hrdina, R., Gerš, V., & Adamcová, M. (2002) · Human & Experimental Toxicology · doi:10.1191/0960327102ht311oa · Cited by 42
Self-citationUsefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs
Unverferth, D. V., Leier, C. V., Balcerzak, S. P., & Hamlin, R. L. (1985) · The American Journal of Cardiology · doi:10.1016/0002-9149(85)90585-5 · Cited by 42
Voest, E. E., van Acker, S. A. B. E., van der Vijgh, W. J. F., van Asbeck, B. S., & Bast, A. (1994) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1994.1136 · Cited by 42
Lim, C. K., Kalinowski, D. S., & Richardson, D. R. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046847 · Cited by 40
Hašková, P., Koubková, L., Jirkovská, A., Macková, E., Hrušková, K., Kovařı́ková, P., Vávrová, K., & Šimůnek, T. (2011) · Toxicology · doi:10.1016/j.tox.2011.08.006 · Cited by 40
Self-citationYiakouvaki, A., Savović, J., Al-Qenaei, A., Dowden, J., & Pourzand, C. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700373 · Cited by 38
Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?
Fulbright, J. M., Huh, W. W., Anderson, P. M., & Chandra, J. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0129-9 · Cited by 38
Carnitine protection against adriamycin-induced cardiomyopathy in rats
McFalls, E. O., Paulson, D. J., Gilbert, E. F., & Shug, A. L. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90028-7 · Cited by 38
Cited by
Mitochondria and Mitophagy: The Yin and Yang of Cell Death Control
Kubli, D. A., & Gustafsson, Å. B. (2012) · Circulation Research · doi:10.1161/circresaha.112.265819 · Cited by 796
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Cappetta, D., De Angelis, A., Sapio, L., Prezioso, L., Illiano, M., Quaini, F., Rossi, F., Berrino, L., Naviglio, S., & Urbanek, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1521020 · Cited by 350
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
Metadata
- Authors
- Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2013-03-10
- Volume
- 18
- Issue
- 8
- Pages
- 899-929
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2036225919
- Cited by
- 329
- References
- 241
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.